(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Olfaction Disorders D000857 17 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Body Weight D001835 333 associated lipids
Brain Diseases D001927 27 associated lipids
Celiac Disease D002446 16 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Chondrodysplasia Punctata D002806 8 associated lipids
Chronic Disease D002908 7 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Edema D004487 152 associated lipids
Exostoses, Multiple Hereditary D005097 3 associated lipids
Fasciitis D005208 2 associated lipids
Fatigue D005221 10 associated lipids
Fibrosarcoma D005354 8 associated lipids
Gallbladder Diseases D005705 3 associated lipids
Hemolysis D006461 131 associated lipids
Hepatitis D006505 11 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipoproteinemia Type III D006952 4 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Keloid D007627 12 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Leukemia, Hairy Cell D007943 5 associated lipids
Lipodystrophy D008060 4 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuroblastoma D009447 66 associated lipids
Niemann-Pick Diseases D009542 25 associated lipids
Dermatitis, Occupational D009783 12 associated lipids
Occupational Diseases D009784 42 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Otitis Media D010033 12 associated lipids
Pain D010146 64 associated lipids
Parkinson Disease D010300 53 associated lipids
Parvoviridae Infections D010322 4 associated lipids
Periodontitis D010518 22 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Photosensitivity Disorders D010787 8 associated lipids
Pneumonia, Lipid D011017 2 associated lipids
Precancerous Conditions D011230 48 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Psoriasis D011565 47 associated lipids
Rosacea D012393 13 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Stomach Ulcer D013276 75 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Tinea Versicolor D014010 5 associated lipids
Viremia D014766 4 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Xanthomatosis D014973 17 associated lipids
Weight Gain D015430 101 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Keratitis, Herpetic D016849 5 associated lipids
Coronavirus Infections D018352 4 associated lipids
Parasitemia D018512 5 associated lipids
Persian Gulf Syndrome D018923 1 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Steatorrhea D045602 2 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Atherosclerosis D050197 85 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Arias JL et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. 2011 ACS Nano pmid:21275408
van den Brand JM et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. 2011 J. Virol. pmid:21209108
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Montagnani S et al. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. 2011 Ann Pharmacother pmid:21189364
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
Lopez P et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. 2011 J. Infect. Dis. pmid:21606530
Cen-Pacheco F et al. Cytotoxic oxasqualenoids from the red alga Laurencia viridis. 2011 Eur J Med Chem pmid:21616566
Raouane M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. 2011 J. Med. Chem. pmid:21561161
Nowosielski M and Hoffmann M Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? 2011 J Mol Model pmid:21562825
Hernández-García I et al. [Adverse events after administration of A/H1N1 vaccine to patients]. 2011 Med Clin (Barc) pmid:20199781
Bernstein DI Vaccines for cytomegalovirus. 2011 Infect Disord Drug Targets pmid:22309618
Fabbiani M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. 2011 Vaccine pmid:21349364
Gill S et al. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. 2011 Cell Metab. pmid:21356516
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Kaya K et al. Thraustochytrid Aurantiochytrium sp. 18W-13a accummulates high amounts of squalene. 2011 Biosci. Biotechnol. Biochem. pmid:22056449
Cheong HJ et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. 2011 Clin. Vaccine Immunol. pmid:21715575
Soto G et al. Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. 2011 J. Exp. Bot. pmid:21908473
Celia C et al. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. 2011 Expert Opin Drug Deliv pmid:22077480
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Puig-Barberà J et al. MF59™-adjuvanted seasonal influenza vaccine in young children. 2011 Expert Rev Vaccines pmid:22043952
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Achiraman S et al. Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? 2011 Theriogenology pmid:21924481
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Wu J et al. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. 2011 Arch. Virol. pmid:21110049
Packwood DM and Phillips LF A stochastic, local mode study of neon-liquid surface collision dynamics. 2011 Phys Chem Chem Phys pmid:21042647
Andrews N et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. 2011 J. Infect. Dis. pmid:21148494
Kajaste-Rudnitski A et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. 2011 AIDS pmid:21150561
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Gao J et al. Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. 2011 J. Am. Soc. Mass Spectrom. pmid:21472571
Weschler CJ et al. Squalene and cholesterol in dust from danish homes and daycare centers. 2011 Environ. Sci. Technol. pmid:21476540
Cauda V et al. "Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. 2011 J. Am. Chem. Soc. pmid:21480591
Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. 2011 Lancet pmid:21481708
Liu CL et al. The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. 2011 Phys Chem Chem Phys pmid:21455529
Inagaki YS et al. Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. 2011 New Phytol. pmid:21501172
Garcia-Sicilia J et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. 2011 Vaccine pmid:21504774
O'Hagan DT et al. MF59 adjuvant: the best insurance against influenza strain diversity. 2011 Expert Rev Vaccines pmid:21506643
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. 2011 Hum Vaccin pmid:21508673
Ačimovič J et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. 2011 Biochem. Biophys. Res. Commun. pmid:21531203
Siedenburg G and Jendrossek D Squalene-hopene cyclases. 2011 Appl. Environ. Microbiol. pmid:21531832
Tsai TF et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. 2011 Scand. J. Infect. Dis. pmid:21534891
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645